Announcements Trials
Browse Landscape

Status

Unknown 1

Sponsor Class

OTHER 8NIH 1NETWORK 1INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Non-Muscle Invasive Bladder Neoplasms 15Urinary Bladder Neoplasms 14Carcinoma, Transitional Cell 14Neoplasms 5Urologic Neoplasms 4Urologic Diseases 3Urogenital Neoplasms 3Urinary Bladder Diseases 3Neoplasms by Site 3Carcinoma 3Recurrence 2Carcinoma in Situ 2Virus Diseases 1Urogenital Diseases 1Neoplasms by Histologic Type 1Neoplasm Recurrence, Local 1Mycobacterium Infections 1Male Urogenital Diseases 1Female Urogenital Diseases 1Disease 1Carcinoma, Hepatocellular 1Adenoviridae Infections 1

Interventions

Sorafenib 79pembrolizumab 37Bevacizumab 36Nivolumab 33lenvatinib 30atezolizumab 24durvalumab 17Oxaliplatin 12Ipilimumab 12regorafenib 9Capecitabine 9tremelimumab 8Injections 8Doxorubicin 8tislelizumab 7sintilimab 7Fluorouracil 7cabozantinib 6budigalimab 6brivanib 6Ramucirumab 6toripalimab 5Gemcitabine 5Everolimus 5Cyclophosphamide 5ADI PEG20 5fludarabine 4Sunitinib 4Leucovorin 4E-7386 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoma, Hepatocellular × Mitomycin × Clear all
NCT00644020 2008-03-26

Phase â…¡Study of Tyroserleutide for Injection in Hepatocellular Carcinoma(HCC) Patients

Shenzhen Kangzhe Pharmaceutical Co., Ltd.

Unknown
100 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡